Lead author, year and country | Population, medication | Design | Age, y | Male (%) | Sample size, N | Duration, days | Fenugreek, preparation | Daily dose, g | Control | Outcomes | Study quality | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RCT | Blinding | Dropout | |||||||||||
Bordia et al., 1997 [42], India | Mild T2DM, NR | PL | NR | NR | 40 | 30 | Capsule, PS | 5 | Placebo | FBG, 2 hr glucose | NR | NR | NR |
Bordia et al., 1997 [42], India | Severe T2DM, NR | PL | NR | NR | 40 | 30 | Capsule, PS | 5 | Placebo | FBG, 2 hr glucose | NR | NR | NR |
Chevassus et al., 2010 [43], France | Overweight, NR | PL | 38.0 | 100 | 40 | 42 | Capsule, H | 1.176 | Placebo | FBG, FSI | Yes | DB | 5% |
Gupta et al., 2001 [23], India | T2DM, SU, BI | PL | 51.0 | 76 | 25 | 56 | Capsule, H | 1 | Placebo | FBG, 2 hr glucose, HbA1c, FSI | Yes | DB | 4% |
Lu et al., 2008 [9], China | T2DM, SU | PL | 54.4 | 55 | 69 | 84 | Capsule, PS | 6.3 | Placebo | FBG, 2 hr glucose, HbA1c | Yes | DB | NR |
Alamdari et al., 2009 [17], Iran | T2DM, Diet, OAD | CO | 43.1 | 100 | 12 | 56 | PS | 8 | Unspecified | FBG, 2 hr glucose, HbA1c | Yes | NR | 25% |
Chevassus et al., 2009 [25], France | Healthy, NR | CO | 22.0 | 100 | 12 | 14 | Capsule, H | 1.176 | Placebo | FBG, FSI | Yes | DB | 0% |
Raghuram et al., 1994 [7], India | T2DM, BI | CO | 46.6 | NR | 10 | 15 | Chapatia, PS | 25 | Chapati | FBG, 1 hr glucose, HbA1c | Yes | NR | NR |
Sharma et al., 1990 [44], India | T1DM, Insulin therapy | CO | 22.7 | 70 | 10 | 10 | Chapatia, DPS | 100 | Chapati | FBG, 2 hr glucose, FSI | Yes | NR | NR |
Sharma et al., 1990 [22], India | T2DM, BI/metformin | CO | 46.0 | 67 | 15 | 10 | Chapatia, DPS | 100 | Chapati | FBG, 2 hr glucose, FSI | Yes | NR | NR |
Sharma et al., 1990 [22], India | T2DM, NR | CO | 42.0 | NR | 5 | 20 | Chapatia, DPS | 100 | Chapati | FBG, 2 hr glucose | Yes | NR | NR |